Rockwell Medical (RMTI) and Keryx (KERX) Move in Opposite Directions
Tweet
Share
E-mailGet Alerts RMTI Hot Sheet
Price: $8.07 --0%
Rating Summary:
12 Buy, 2 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 14 | New: 22
Rating Summary:
12 Buy, 2 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 14 | New: 22
Join SI Premium – FREE
Several related biotech stocks were on the move on Tuesday, Rockwell Medical, Inc. (Nasdaq: RMTI), which traded lower, and Keryx Biopharmaceuticals Inc. (Nasdaq: KERX), which traded higher. Kerx is developing an iron drug for kidney disease patients. Rockwell reported phase 3 data on its experimental iron drug on July 11th. On July 12th, Brean analyst Jonathan Aschoff said results were hardly a threat to Keryx.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Starts Vishay Intertechnology (VSH) at Buy
- Activist Elliott Is Said To Build Stake In Deutsche Telekom - Bloomberg
- Blackstone Private Credit Fund To Cap Redemptions At 5% Again - Bloomberg
Create E-mail Alert Related Categories
Analyst Comments, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
